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Abstract
Purpose A recent dose-finding study showed no significant
differences in number of mature oocytes, embryos and top-
quality embryos when triptorelin doses of 0.2, 0.3 or 0.4 mg
were used to trigger final oocyte maturation in oocyte donors
co-treated with a gonadotropin-releasing hormone (GnRH)
antagonist. This analysis investigated whether triptorelin dos-
ing for triggering final oocyte maturation in oocyte donors
induced differences in follicular fluid (FF) hormone levels
and granulosa cell gene expression.
Methods This single-centre, randomised, parallel, investigator-
blinded trial was conducted in oocyte donors undergoing a
single stimulation cycle at IVFMD, My Duc Hospital, Ho
Chi Minh City, Vietnam, from August 2014 to March 2015.
A total of 165 women aged 18–35 years with body mass index
<28 kg/m2, anti-Müllerian hormone >1.25 ng/mL, and antral
follicle count ≥6 were randomised to three different triptorelin
doses for trigger. The main outcome was concentration of ste-
roid hormones in FF collected from the first punctured follicle
on each side. Moreover, luteinising hormone receptor (LHR),
3β-hydroxy-steroid-dehydrogenase (3ßHSD) and inhibin-Ba
(INHB-A) gene expression in cumulus and mural granulosa
cells were investigated in a subset of women from each group.
Results Progesterone and oestradiol levels in FF did not differ
significantly by trigger doses; findings were similar for
3βHSD, LHR and INHB-A gene expression in both cumulus
and mural granulosa cells.
Conclusions In women co-treated with a GnRH antagonist,
no significant differences in FF steroid levels and granulosa
cell gene expression were seen when different triptorelin
doses were used to trigger final oocyte maturation.
Keywords In vitro fertilisation . Gonadotropin-releasing
hormone agonist trigger . LHR gene expression . Triptorelin .
Follicular fluid
Introduction
Since the introduction of gonadotropin-releasing hormone
(GnRH) antagonists for the prevention of a premature lutein-
ising hormone (LH) surge, GnRH agonists (GnRHa) have
played an important role in triggering final oocyte maturation
[1–4]. Based on a number of advantages, of which the signif-
icant reduction of ovarian hyperstimulation syndrome is the
most prominent, GnRHa trigger has become the trigger agent
of choice for oocyte donors worldwide [5].
Until recently, there were no dose findings studies on
GnRHa trigger. However, the results of a recent randomised,
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investigator-blinded study showed that there were no signifi-
cant differences between triptorelin doses of 0.2, 0.3 and
0.4 mg when used for triggering of final oocyte maturation
in oocyte donors as regards the number of mature oocytes,
top-quality embryos, ovarian volume and luteal phase dura-
tion [6]. In addition, there were practically no between-group
differences in serum concentrations of LH, follicle-stimulating
hormone (FSH), oestradiol and progesterone during the follic-
ular and early luteal phases [6].
The follicular fluid (FF) surrounds the oocyte and its com-
position is profoundly influenced by the granulosa cell secre-
tions, functioning as a mediator of signalling substances that
are transported between cell types within the follicle and the
surroundings [7]. In women undergoing assisted reproductive
technologies, FF is easily accessible, allowing analysis of hor-
mones and granulosa cell gene expression to determine the
impact of ovarian stimulation and the maturation trigger on
oocyte maturation.
To further assess the comparability of different triptorelin
doses used for trigger [6], the present study (NCT02208986)
analysed steroid profiles in FF, and cumulus cell and mural
granulosa cells gene expression profiles in GnRH antagonist
co-treated women, randomised to three different GnRHa trig-
ger doses.
Materials and methods
This single-centre, randomised controlled trial was conducted
from August 2014 to March 2015 at IVFMD, My Duc
Hospital, Ho Chi Minh City, Vietnam. All women provided
written informed consent to participate in the study, which was
conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice. The Institutional Review Board (IRB)
and Ethics Committee approved the study protocol on 21
July 2014 (IRB reference number: NCKH/CGRH_01_2014,
and Clinicaltrial.gov registration: NCT02208986). Primary
outcome results have been published previously [6].
Subjects
All oocyte donors who met the following criteria were eligible
for inclusion in the study: age 18–35 years, body mass index
(BMI) <28 kg/m2, normal ovarian reserve (anti-Müllerian hor-
mone [AMH] >1.25 ng/mL or antral follicle count [AFC] ≥6
[8] measured within 2 months prior to the start of stimulation),
first oocyte donation cycle stimulated with rec FSH and co-
treated with a GnRH antagonist, and willingness/ability to
comply with protocol requirements for the duration of the
study. Exclusion criteria were as follows: polycystic ovary
syndrome (PCOS), WHO group 1 anovulation, chronic med-
ical condition (e.g., diabetes, Crohn’s disease, thyroid disease,
hepatitis B or sexually transmitted diseases), participation in
another clinical trial or concomitant use of either LH or human
menopausal gonadotropin (hMG)/urinary FSH preparations
during the study cycle.
Stimulation, monitoring and oocyte pick-up
Oocyte donors were randomised to trigger with subcutaneous
triptorelin (Ipsen Pharma Biotech, France) at a dose of either
0.2, 0.3 or 0.4 mg. Randomisation was performed using sealed
envelopes developed via a computer-generated list with
blocks of nine. Physicians, but not women and nurses, were
blinded to treatment allocation. Stimulation was performed
according to the standard protocol of the unit, using a depot
injection of corifollitropin alfa (Elonva®; 100 or 150 μg based
on bodyweight) on cycle day 2, followed by co-treatment with
a GnRH antagonist (Ganirelix®) and follitropin beta, 150 IU/
day from day 8 of simulation until the day of triggering. When
two follicles had reached a size of ≥17 mm, triptorelin was
given to trigger final oocyte maturation.
Follicular fluid and hormone level determination
On the day of ovum pick-up, follicular fluid was collected
from the first punctured follicle on each side, centrifuged
and then cryopreserved at −20°C for subsequent analysis of
levels of two important granulosa cell secreted steroids.
Progesterone and oestradiol concentrations were measured in
individual follicle fluids using commercially available ELISA
kits (progesterone: DNOV006, Novatec; 17β-oestradiol:
DNO003, Novatec, Immundiagnostica GmBH, Germany). A
phosphate-buffered saline (PBS) solution containing 1% bo-
vine serum albumin (BSA) was used for dilution of the FF
samples prior to measurements according to the manufac-
turer’s instructions. Dilutions of 1:1000 were used for all sam-
ples for both progesterone and oestradiol measurements,
which resulted in readings inside the standard curve. All sam-
ples were run in duplicate and the mean value was used for
further calculations. The intra-assay and inter-assay variations
were ≤9 and ≤10%, respectively, for oestradiol ELISA, and ≤4
and ≤9.3%, respectively, for progesterone ELISA.
Expression of genes affected by the mid-cycle surge
and of importance for the luteal phase
Cumulus and mural granulosa cells from oocyte(s) from the first
follicle in the last 10 women recruited to each triptorelin dosage
group were isolated immediately after ovum pick-up and snap
frozen for analysis of 3β-hydroxy-steroid-dehydrogenase
(3ßHSD) catalysing conversion of pregnelonone to progester-
one, luteinising hormone receptor (LHR) stimulating progester-
one secretion and inhibin beta A (IHNB-A) gene expression,
which becomes heavily upregulated in connection with the
mid-cycle surge of gonadotropins. Purification of RNA was
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performed using Agilent Absolutely RNA nanoprep kit (Agilent
Technologies #400753, Santa Clara, USA). All steps were per-
formed on ice. First-strand cDNA synthesis was carried out
using Applied Biosystems High Capacity cDNA reverse tran-
scription kit (Applied Biosystems #4368814, Foster City, USA,
lot: 1311191). The synthesis was performed on a thermal cycler
(ThermoFisher Scientific Arktik thermal block, Vantaa, Finland)
with the following temperature profiles: 25°C for 10 min, 37°C
for 120 min, 85°C for 5 s and 4°C until termination. For qPCR,
TaqMan Universal PCR master mix (Applied Biosystems, cat.
#4304437, Warrington, UK, lot: 1311066) was used as well as
the pre-designed TaqMan probes tagged with FAM labelling
(Appl ied Biosys tems , Fos te r Ci ty, USA): LHR
(Hs00174885_m1), 3βHSD (Hs01084547_gH) and INHB-A
(Hs01081598_m1), plus glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (Hs02758991_g1) as housekeeping gene.
qPCR reactions were performed in a total volume of 10 μL
consisting of a mixture of 0.5 μL 20× TaqMan gene expression
assay (TaqMan probe), 0.5 μL 2× TaqMan Universal PCRmas-
ter mix, 2 μL cDNA and 2.5 μL RNase free water for each
reaction. The 96-well qPCR plates (white multiwell plates 96,
Roche Diagnostics, cat. #04729692001, Mannheim, Germany)
were centrifuged for 1 min at 1000g prior to analysis using the
Lightcycler 480 (LightCycler480 II, Roche Diagnostics,
Mannheim, Germany). Forty-five cycles of the following PCR
program were used: 50°C for 2 min (pre-incubation), 95°C for
10 min, 95°C for 15 s, 60°C for 1 min and finally 40°C for 30 s.
All samples were run in duplicates and normalised to GAPDH
gene expression levels. Calculation of the expression level of the
gene of interest was carried out according to the comparative CT
method for relative quantification of gene expression.
Outcome measures
The main outcome measure of this analysis was the level of
steroid hormones (oestradiol and progesterone) in FF.
Secondary outcome measures were mural and cumulus LHR
gene expression.
Statistical analysis
This study was based on a previous randomised trial [6].
Sample size was calculated based on the primary endpoint in
the main trial (i.e., determining non-inferiority for the number
ofMII oocytes in the three different triptorelin dosage groups).
The present analysis had a different primary endpoint (steroid
hormone levels in follicular fluid). Therefore, we performed a
post hoc power calculation [9] to determine whether the sam-
ple size of the main trial was sufficient to provide enough
power to assess the primary endpoint used in this analysis.
The power calculation for one-way analysis of variance tests
included the following parameters: number of groups (k) = 3;
number of samples in each group = 55; effect size ( f ) = 0.03;
and alpha = 0.05. This provided a power of 82% for the cur-
rent analysis.
Statistical analysis was performed using SPSS 20.0. All
tests were two-tailed, and a p value of <0.05 was considered
statistically significant. Continuous variables are presented as
mean ± SEM and were tested using analysis of variance with a
post hoc test. Categorical data were expressed as numbers and
compared, using the Fisher’s exact test.
Results
A total of 165 women were enrolled in the study, receiving
trigger with either triptorelin 0.2 mg (n = 55), 0.3 mg (n = 55)
or 0.4 mg (n = 55). A CONSORT flow diagram is shown in
Fig. 1. There were no significant differences between treat-
ment groups in patient characteristics at baseline and overall
cycle characteristics (Table 1). In addition, patient character-
istics for the 10 women in each group who underwent gene
profiling were similar to those of the total study population
(Table 1). The effects of the different triptorelin doses on oo-
cyte and embryo outcomes have been reported previously [6].
There were no significant differences between women treated
with triptorelin 0.2, 0.3 or 0.4 mg as regards the number of
MII oocytes, cleavage rates and the number of top-quality
embryos. In addition, the early- and late-luteal-phase steroid
profiles were quite similar, and no differences were seen in
ovarian volume during the luteal phase [6]. FF analyses were
conducted in all 165 enrolled women across the three GnRa
trigger dose groups, while gene expression analysis was un-
dertaken in 10 women from each triptorelin dose group.
Follicular fluid hormone levels
Progesterone levels in FF were 48,916 ± 4011 nmol/L in the
triptorelin 0.2 mg group, 40,240 ± 3760 nmol/L in the 0.3 mg
group and 48,165 ± 5093 nmol/L in the 0.4 mg group, with no
significant between-group differences (Fig. 2a). Values for FF
oestradiol in the triptorelin 0.2, 0.3 and 0.4 mg groups were
also similar, at 1773 ± 260, 1961.3 ± 335 and 1532 ±
257 nmol/L, respectively (Fig. 2b). Between-group differ-
ences in oestradiol and progesterone levels with the upper
and lower bounds of the confidence limit confirmed that there
were no statistically significant differences between groups in
FF steroid hormone levels (Table 2).
Gene expression
The expression of 3β-HSD, LHR and IHNB-A genes in both
cumulus cells and mural granulosa cells did not differ signif-
icantly after ovulation trigger with either triptorelin 0.2, 0.3 or
0.4 mg (Figs. 3 and 4).
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Table 1 Patient and cycle
characteristics at baseline Triptorelin p value
0.2 mg 0.3 mg 0.4 mg
All patients (n = 55) (n = 55) (n = 55)
Age, years 27.9 ± 4.6 26.8 ± 3.9 27.1 ± 4.2 0.38a
BMI, kg/m2 21.1 ± 2.4 20.4 ± 2.8 21.0 ± 2.9 0.89a
AMH, ng/mL 6.8 ± 3.3 7.4 ± 3.3 7.1 ± 3.9 0.62a
AFC, total number 18.0 ± 6.2 19.0 ± 7.3 18.0 ± 6.1 0.97a
Corfollitropin alfa dose, n (%) 0.43b
100 μg 47 (85.5) 51 (92.7) 47 (85.5)
150 μg 8 (14.5) 4 (7.3) 8 (14.5)
Duration of stimulation, days 10.4 ± 1.4 10.4 ± 1.5 10.5 ± 1.5 0.69a
Total dose of follitropin beta, IU 540.0 ± 113.6 490.0 ± 155.6 565.5 ± 142.2 0.76a
Patients who underwent gene profiling (n = 10) (n = 10) (n = 10)
Age, years 27.40 ± 3.75 29.90 ± 4.12 27.00 ± 3.68 0.21a
BMI, kg/m2 20.87 ± 1.70 20.59 ± 1.34 21.68 ± 2.95 0.50a
AMH, ng/mL 6.49 ± 2.94 6.00 ± 3.28 8.59 ± 4.07 0.23a
AFC, total number 13.60 ± 4.12 14.60 ± 7.62 19.70 ± 5.29 0.06a
Corfollitropin alfa dose, n (%) 0.29b
100 μg 9 (90.0) 10 (100.0) 7 (70.0)
150 μg 1 (10.0) 0 (0.0) 3 (30.0)
Duration of stimulation, days 9.90 ± 1.20 10.50 ± 1.72 10.10 ± 1.97 0.72a
Total dose of follitropin beta, IU 685.00 ± 333.37 850.00 ± 471.99 695.00 ± 451.20 0.63a
Data are presented as mean ± standard deviation or number of patients (%)
AFC antral follicle count, AMH anti-Müllerian hormone, BMI body mass index
aAnalysis of variance
b Fisher’s exact test
Fig. 1 CONSORT flow diagram.
AMH anti-Müllerian hormone,
COS controlled ovarian
stimulation, GnRH gonadotropin-
releasing hormone, OPU oocyte
pick-up, PCOS polycystic ovary
syndrome
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Discussion
This study showed no differences in FF steroid hormone
levels and no differences in either mural or cumulus cell gene
expression profiles in human follicles triggered with one of
three different doses of triptorelin (0.2, 0.3 or 0.4 mg). This
confirms and extends previous clinical results showing similar
outcomes with respect to oocyte number, maturity and quality,
regardless of the GnRHa trigger dose used [5, 6].
The fact that the GnRHa-induced gonadotropin surge suc-
cessfully induces full oocyte maturation although the surge is
of shorter duration and with a significant difference in profile
compared with the natural mid-cycle surge of gonadotropins
[10, 11] demonstrates that the threshold level of LH-like ac-
tivity required to induce oocyte maturation is lower than seen
during natural cycle.
These results are in accordance with data from the rat mod-
el in which it was shown that ovulation per se requires an LH-
like activity of around 85% of the natural mid-cycle surge of
gonadotropins, whereas oocyte maturation occurs when folli-
cles are exposed to around one third of the natural mid-cycle
surge of gonadotropins [12]. As a consequence, the use of an
Fig. 2 Hormone levels (a progesterone and b oestradiol) in follicular fluid after trigger using triptorelin 0.2, 0.3 and 0.4 mg
Table 2 Between-group
differences in oestradiol and
progesterone levels
Mean difference
between doses
95% confidence limit Adjusted p value
Lower Upper
Oestradiol level
Triptorelin 0.3–0.2 mg 188.34 −765.98 1142.66 0.887
Triptorelin 0.4–0.2 mg −241.11 −1204.56 722.34 0.825
Triptorelin 0.4–0.3 mg −429.45 −1392.90 534.01 0.544
Progesterone level
Triptorelin 0.3–0.2 mg −8675.74 −22996.97 5645.49 0.326
Triptorelin 0.4–0.2 mg −751.49 −15,209.77 13,706.79 0.992
Triptorelin 0.4–0.3 mg 7924.25 −6534.03 22,382.53 0.399
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hCG trigger, e.g., 10,000 IU, which is considered the gold
standard, characterised by an extended half-life and supra-
physiological levels of LH-like activity, will provide a signal
for final maturation of oocytes which by far exceeds the
amount necessary [13].
Collectively, the present results suggest that final matura-
tion of oocytes, using an endogenously released mid-cycle
surge, is relatively insensitive to the dose of GnRHa used
and that even a relatively small bolus of GnRHa is capable
of inducing oocyte maturation in women with the same char-
acteristics as our study population. Moreover, the data corrob-
orate previous research, supporting the idea that different
types of GnRHa and different pharmacological doses of
GnRHa may be used for final maturation of oocytes without
negatively impacting the oocyte maturation rate and the oo-
cyte quality [5].
In an early study showing that the FF fluid microenviron-
ment prior to ovulation is dependent on the method by which
ovulation is triggered, concentrations of inhibin and proges-
terone in FF were significantly higher after triggering with
hCG versus GnRHa [14]. Subsequent studies confirmed and
extended these findings, with higher FF progesterone and
amphiregulin levels seen after hCG trigger compared with
GnRHa trigger [15, 16]. Moreover, significant differences in
early luteal endometrial gene-expression profiles were seen
when comparing hCG trigger to GnRHa trigger [17].
Furthermore, differences between GnRHa and hCG trigger
have been documented for gene expression profiles in granu-
losa and cumulus cells, with LH suggested to be the upstream
regulator responsible for these observations [18]. Differences
are likely to reflect that a standard hCG trigger induces supra-
physiological levels of LH-like activity which boosts ovarian
steroidogenesis in a more pronounced way than a GnRHa
trigger. In contrast, the GnRHa trigger has a reduced stimula-
tory effect on steroidogenesis as compared to that of the nat-
ural mid-cycle surge of gonadotropins; however, full oocyte
maturation is still achieved. Importantly, the risk of ovarian
hyperstimulation syndrome (OHSS) is significantly lower af-
ter GnRHa compared with hCG trigger [5, 6, 19–21].
Based on the equivalence of the triptorelin doses stud-
ied with respect to oocyte number, maturity and quality
[6], the lack of a significant difference between dose
groups with respect to FF steroid hormone levels is not
unexpected. However, variations in gene expression war-
rant further investigation in larger patient groups.
Although our data from 10 patients showed no significant
Fig. 3 Gene expression in cumulus cells, normalised to glyceraldehyde
3-phosphate dehydrogenase (GAPDH), after trigger using triptorelin 0.2,
0.3 and 0.4 mg. a 36-Hydroxysteroid dehydrogenase (HSD). b
Luteinising hormone receptor (LHR). c Inhibin beta A (IHNB-A)
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between-group differences, values were not always con-
sistent across triptorelin doses, suggesting that gene ex-
pression in cumulus and mural granulosa cells may be
more sensitive to the GnRHa trigger dose.
Limitations of the present study are that the analysis was
performed in an Asian population only, and that the GnRHa
trigger doses studied theoretically may not be applicable to
other clinical settings and countries; moreover, the inclusion
of oocyte donors only limits the ability to generalise the results
to a wider population of women undergoing infertility treat-
ment. Finally, the gene expression analysis was performed in a
subset of women from each dosing group (10 for each
triptorelin dose), potentially reducing the power of this analy-
sis. Although we did not find statistically significant between-
group differences, some dose-dependent trends in gene ex-
pression can be seen in the figures, particularly for HSD gene
expression in mural granulosa cells (Fig. 4a). Therefore, it is
possible that these could reach statistical significance if
analysed in a larger group of patients. Nevertheless, the cur-
rent data corroborate previous clinical findings [6], which
combined provide a complete picture of the effects of the
different GnRHa trigger doses studied.
In conclusion, no significant differences in follicular fluid
levels of steroid hormones and granulosa cell gene expression
were seen in oocyte donors co-treated with a GnRH antagonist
when triptorelin doses ranging from 0.2 to 0.4 mg were used
to trigger final oocyte maturation. These findings, and results
in the same patients showing no influence of triptorelin dose
on oocyte number, maturity and quality, favour the use of the
lower triptorelin trigger dose.
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